These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32584426)

  • 1. Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
    Park S; Shim J; Mortimer PGS; Smith SA; Godin RE; Hollingsworth SJ; Kim HJ; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
    Cancer; 2020 Sep; 126(17):4002-4012. PubMed ID: 32584426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive
    Oza AM; Estevez-Diz M; Grischke EM; Hall M; Marmé F; Provencher D; Uyar D; Weberpals JI; Wenham RM; Laing N; Tracy M; Freshwater T; Lee MA; Liu J; Qiu J; Rose S; Rubin EH; Moore K
    Clin Cancer Res; 2020 Sep; 26(18):4767-4776. PubMed ID: 32611648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Park S; Kim YJ; Min YJ; Mortimer PGS; Kim HJ; Smith SA; Dean E; Jung HA; Sun JM; Park WY; Ahn JS; Ahn MJ; Lee SH; Park K
    Cancer; 2024 Feb; 130(4):541-552. PubMed ID: 37843249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
    Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
    Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
    Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
    J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.
    Almodovar K; Iams WT; Meador CB; Zhao Z; York S; Horn L; Yan Y; Hernandez J; Chen H; Shyr Y; Lim LP; Raymond CK; Lovly CM
    J Thorac Oncol; 2018 Jan; 13(1):112-123. PubMed ID: 28951314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
    Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
    Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
    Edelman MJ; Redman MW; Albain KS; McGary EC; Rafique NM; Petro D; Waqar SN; Minichiello K; Miao J; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
    J Thorac Oncol; 2019 Oct; 14(10):1853-1859. PubMed ID: 31302234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
    Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R; Deng X; Sun SY; Rossi MR; Sica GL; Ramalingam SS; Khuri FR
    J Transl Med; 2016 May; 14(1):111. PubMed ID: 27142472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of WEE1 Is Effective in
    Seligmann JF; Fisher DJ; Brown LC; Adams RA; Graham J; Quirke P; Richman SD; Butler R; Domingo E; Blake A; Yates E; Braun M; Collinson F; Jones R; Brown E; de Winton E; Humphrey TC; Parmar M; Kaplan R; Wilson RH; Seymour M; Maughan TS;
    J Clin Oncol; 2021 Nov; 39(33):3705-3715. PubMed ID: 34538072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.
    Lycan TW; Pardee TS; Petty WJ; Bonomi M; Alistar A; Lamar ZS; Isom S; Chan MD; Miller AA; Ruiz J
    PLoS One; 2016; 11(10):e0164244. PubMed ID: 27732654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
    Morscher RJ; Brard C; Berlanga P; Marshall LV; André N; Rubino J; Aerts I; De Carli E; Corradini N; Nebchi S; Paoletti X; Mortimer P; Lacroix L; Pierron G; Schleiermacher G; Vassal G; Geoerger B
    Eur J Cancer; 2021 Nov; 157():268-277. PubMed ID: 34543871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
    Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
    Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
    Leijen S; van Geel RM; Sonke GS; de Jong D; Rosenberg EH; Marchetti S; Pluim D; van Werkhoven E; Rose S; Lee MA; Freshwater T; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Dec; 34(36):4354-4361. PubMed ID: 27998224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
    Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
    Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.
    Kim YJ; Keam B; Ock CY; Song S; Kim M; Kim SH; Kim KH; Kim JS; Kim TM; Kim DW; Lee JS; Heo DS
    Lung Cancer; 2019 Oct; 136():122-128. PubMed ID: 31494530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.